LCTX
Price
$0.91Alerts
Change
-$0.08 (-8.08%)
Updated
Nov 13 closing price
Capitalization
257.97M
116 days until earnings call
Intraday BUY SELL Signals
VIR
Price
$9.96Alerts
Change
-$2.16 (-17.82%)
Updated
Nov 13 closing price
Capitalization
2.07B
102 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

LCTX vs VIR

LCTX vs VIR Comparison Chart in %
loading
loading
View a ticker or compare two or three
A.I.Advisor
Nov 07, 2026

Which Stock Would AI Choose? Lineage Cell Therapeutics (LCTX) vs. Vir Biotechnology (VIR) Stock Comparison

Key Takeaways

  • Both companies are clinical-stage biotechs, but LCTX develops "off-the-shelf" cell replacement therapies while VIR pursues infectious-disease and immuno-oncology programs.
  • VIR has demonstrated materially stronger recent momentum and holds a substantially larger cash position, supporting a longer operating runway.
  • LCTX carries a "Strong Buy" analyst consensus and a wide price-target spread, but its share price has trended lower in recent months.
  • Tickeron AI Verdict: VIR — the AI model currently favors VIR based on trend consistency, stability, and a nearer-term catalyst schedule.
  • For deeper coverage, explore LCTX Major News and LCTX Today's Price Move, plus VIR Major News and VIR Today's Price Move.
  • Interested in automated strategies? Browse the curated Trending AI Robots to see which bots are best suited to current market conditions.

Introduction

Investors comparing LCTX and VIR are effectively weighing two distinct biotechnology strategies. Lineage Cell Therapeutics is a small-cap developer of allogeneic (off-the-shelf) cell therapies for degenerative conditions, while Vir Biotechnology is a larger clinical-stage company spanning infectious diseases and emerging cancer immunotherapy. Both stocks are volatile, research-intensive names with limited commercial revenue, making their relative performance heavily dependent on clinical data, partnerships, and financing. This stock comparison is most relevant to growth-oriented and event-driven investors who are comfortable with binary clinical outcomes and who want to understand how market positioning, catalysts, and balance-sheet strength currently differentiate the two.

LCTX Overview and Recent Performance

Lineage Cell Therapeutics (LCTX) develops allogeneic cell replacement therapies built on its AlloSCOPE manufacturing platform. Its most advanced asset, OpRegen, a retinal pigment epithelium (RPE) cell therapy for dry age-related macular degeneration, is partnered with Roche/Genentech. Additional programs include OPC1 for spinal cord injury and earlier-stage efforts such as ReSonance for hearing loss and COR1 for corneal disease. The company generates minimal revenue, recently in the low-single-digit millions per quarter, and reports consistent net losses.

In recent market activity, LCTX has trended lower, with the share price trading near the bottom of its 52-week range and a market capitalization of roughly $258 million. Despite this pullback, sell-side coverage remains optimistic, with a "Strong Buy" consensus and an average price target well above the current price. Cash and marketable securities of around $53 million support operations into 2028, but reliance on partnership milestones and future financing remains a key sensitivity for sentiment.

VIR Overview and Recent Performance

Vir Biotechnology (VIR) is a clinical-stage biopharmaceutical company focused on serious infectious diseases and cancer. Its lead hepatitis delta program pairs elebsiran and tobevibart, with Phase 3 ECLIPSE trials reporting topline data in the near term. In oncology, its PRO-XTEN platform underpins masked T-cell engagers — engineered proteins that direct immune cells toward tumor targets — including VIR-5500 (targeting PSMA in prostate cancer), partnered with Astellas, and earlier-stage HER2 and EGFR programs. A recent research collaboration with Gilead provided additional external validation.

Unlike LCTX, VIR has exhibited strong upward momentum in recent months, gaining substantially on a year-to-date basis and outperforming the broader market. The company ended its most recent quarter with roughly $900 million in cash and investments, plus additional proceeds from the Gilead agreement, extending its runway into the second half of 2028. Recent catalysts, including a U.S. FDA (Food and Drug Administration) Fast Track designation and proof-of-concept progress for VIR-5500, have reinforced positive sentiment.

Trending AI Robots

Tickeron operates hundreds of AI trading bots that collectively trade thousands of different tickers, but only a select group earns placement in the Trending AI Robots section. This curated list highlights the bots best aligned with current market conditions, each with its own trading style, strategy, timeframe, performance history, and basket of tickers. Because no single approach suits every environment, the page helps traders identify automated strategies whose recent performance and configuration are resonating with today's market. If you want to see how AI-driven strategies are currently approaching names like LCTX and VIR, explore the Trending AI Robots page.

Head-to-Head Comparison

The core contrast between these two stocks lies in scale, momentum, and catalyst timing. VIR is a substantially larger company with a diversified late-stage and preclinical pipeline, a nine-figure cash balance, and multiple near-term readouts. LCTX is smaller, more dependent on a single partnered program (OpRegen) and its manufacturing platform, and holds a much thinner cash reserve relative to its spending.

In terms of relative performance, VIR has shown stronger trend consistency and stability, while LCTX has experienced a downward drift despite bullish analyst targets. Risk factors also differ: LCTX faces financing and partnership-concentration risk, whereas VIR faces binary clinical risk concentrated in its hepatitis delta readouts and competitive scrutiny in oncology. Sector exposure is another trade-off — cell therapy versus T-cell engagers and antivirals — each carrying its own regulatory and reimbursement profile.

Tickeron AI Verdict

Based on observable factors such as trend consistency, stability, balance-sheet strength, and the density of near-term catalysts, Tickeron's AI would currently favor VIR. The stock's sustained positive momentum, larger cash runway, and multiple upcoming data events present a comparatively stronger market positioning than LCTX, which is trending lower and remains more dependent on a narrower set of catalysts. This assessment reflects a probabilistic, model-driven comparison of relative positioning rather than a definitive forecast, and conditions could shift as new data and market developments emerge.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

VS
LCTX vs. VIR commentary
Nov 16, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is LCTX is a StrongBuy and VIR is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for LCTX with price predictions
Nov 13, 2026

LCTX in upward trend: price may ascend as a result of having broken its lower Bollinger Band on November 13, 2026

LCTX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 24 of 27 cases where LCTX's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 89%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The 10-day moving average for LCTX crossed bullishly above the 50-day moving average on November 04, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 18 of 21 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 86%.

Following a +9.86% 3-day Advance, the price is estimated to grow further. Considering data from situations where LCTX advanced for three days, in 159 of 210 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.

The Aroon Indicator entered an Uptrend today. In 125 of 156 cases where LCTX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 80%.

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 55 of 66 cases where LCTX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 83%.

The Momentum Indicator moved below the 0 level on November 12, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on LCTX as a result. In 100 of 119 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 84%.

The Moving Average Convergence Divergence Histogram (MACD) for LCTX turned negative on November 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 51 similar instances when the indicator turned negative. In 40 of the 51 cases the stock turned lower in the days that followed. This puts the odds of success at 78%.

LCTX moved below its 50-day moving average on November 12, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where LCTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 26 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.235) is normal, around the industry mean (3.498). P/E Ratio (-7.286) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.060) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.658) among similar stocks. P/S Ratio (20.243) is also within normal values, averaging (440.869).

The Tickeron PE Growth Rating for this company is 34 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 73 (best 1 - 100 worst), indicating slightly worse than average price growth. LCTX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LCTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
a Summary for VIR with price predictions
Nov 13, 2026

VIR in downward trend: price expected to drop as it breaks its higher Bollinger Band on November 09, 2026

VIR broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 41 similar instances where the stock broke above the upper band. In 38 of the 41 cases the stock fell afterwards. This puts the odds of success at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for VIR moved out of overbought territory on November 10, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 28 similar instances where the indicator moved out of overbought territory. In 25 of the 28 cases, the stock moved lower in the following days. This puts the odds of a move lower at 89%.

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 44 of 53 cases where VIR's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 83%.

The Momentum Indicator moved below the 0 level on November 13, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on VIR as a result. In 76 of 92 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 83%.

The Moving Average Convergence Divergence Histogram (MACD) for VIR turned negative on November 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In 35 of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at 83%.

VIR moved below its 50-day moving average on November 13, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where VIR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.

Bullish Trend Analysis

The 10-day moving average for VIR crossed bullishly above the 50-day moving average on October 30, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 76%.

Following a +23.82% 3-day Advance, the price is estimated to grow further. Considering data from situations where VIR advanced for three days, in 205 of 268 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.

The Aroon Indicator entered an Uptrend today. In 125 of 158 cases where VIR Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 79%.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 19 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.103) is normal, around the industry mean (3.498). P/E Ratio (-6.898) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.658) among similar stocks. P/S Ratio (5.168) is also within normal values, averaging (440.869).

The Tickeron Price Growth Rating for this company is 41 (best 1 - 100 worst), indicating steady price growth. VIR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 81 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VIR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

FUNDAMENTALS RATINGS
LCTX vs VIR: Fundamental Ratings
LCTX
VIR
OUTLOOK RATING
1..100
1150
VALUATION
overvalued / fair valued / undervalued
1..100
26
Undervalued
19
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9896
PRICE GROWTH RATING
1..100
7341
P/E GROWTH RATING
1..100
3481
SEASONALITY SCORE
1..100
90n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

VIR's Valuation (19) in the null industry is in the same range as LCTX (26). This means that VIR’s stock grew similarly to LCTX’s over the last 12 months.

VIR's Profit vs Risk Rating (100) in the null industry is in the same range as LCTX (100). This means that VIR’s stock grew similarly to LCTX’s over the last 12 months.

VIR's SMR Rating (96) in the null industry is in the same range as LCTX (98). This means that VIR’s stock grew similarly to LCTX’s over the last 12 months.

VIR's Price Growth Rating (41) in the null industry is in the same range as LCTX (73). This means that VIR’s stock grew similarly to LCTX’s over the last 12 months.

LCTX's P/E Growth Rating (34) in the null industry is somewhat better than the same rating for VIR (81). This means that LCTX’s stock grew somewhat faster than VIR’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
LCTXVIR
RSI
ODDS (%)
N/A
Bearish Trend 3 days ago
89%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
83%
Bearish Trend 3 days ago
83%
Momentum
ODDS (%)
Bearish Trend 3 days ago
84%
Bearish Trend 3 days ago
83%
MACD
ODDS (%)
Bearish Trend 3 days ago
78%
Bearish Trend 3 days ago
83%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
83%
Bearish Trend 3 days ago
81%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
84%
Bearish Trend 3 days ago
78%
Advances
ODDS (%)
Bullish Trend 7 days ago
76%
Bullish Trend 7 days ago
76%
Declines
ODDS (%)
Bearish Trend 3 days ago
83%
Bearish Trend 3 days ago
81%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
89%
Bearish Trend 3 days ago
90%
Aroon
ODDS (%)
Bullish Trend 3 days ago
80%
Bullish Trend 3 days ago
79%
COMPARISON
Comparison
Nov 16, 2026
Stock price -- (LCTX: $0.91 vs. VIR: $9.96)
Brand notoriety: LCTX and VIR are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: LCTX: 138% vs. VIR: 625%
Market capitalization -- LCTX: $257.97M vs. VIR: $2.07B
LCTX [@Biotechnology] is valued at $257.97M. VIR’s [@Biotechnology] market capitalization is $2.07B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $138.67B. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

LCTX’s FA Score shows that 1 FA rating(s) are green while VIR’s FA Score has 1 green FA rating(s).

  • LCTX’s FA Score: 1 green, 4 red.
  • VIR’s FA Score: 1 green, 4 red.
According to our system of comparison, both LCTX and VIR are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

LCTX’s TA Score shows that 4 TA indicator(s) are bullish while VIR’s TA Score has 3 bullish TA indicator(s).

  • LCTX’s TA Score: 4 bullish, 5 bearish.
  • VIR’s TA Score: 3 bullish, 7 bearish.
According to our system of comparison, LCTX is a better buy in the short-term than VIR.

Price Growth

LCTX (@Biotechnology) experienced а -10.33% price change this week, while VIR (@Biotechnology) price change was -18.43% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -3.38%. For the same industry, the average monthly price growth was -5.88%, and the average quarterly price growth was -18.27%.

Reported Earning Dates

LCTX is expected to report earnings on Mar 11, 2027.

VIR is expected to report earnings on Feb 25, 2027.

Industries' Descriptions

@Biotechnology (-3.38% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
Interact to see
Advertisement

LCTX and

Correlation & Price change

A.I.dvisor indicates that over the last year, LCTX has been loosely correlated with EDIT. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if LCTX jumps, then EDIT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LCTX
1D Price
Change %
LCTX100%
-7.64%
EDIT - LCTX
44%
Loosely correlated
+1.40%
MDGL - LCTX
43%
Loosely correlated
+0.51%
IMNM - LCTX
41%
Loosely correlated
+0.37%
FHTX - LCTX
41%
Loosely correlated
+0.98%
VIR - LCTX
40%
Loosely correlated
-17.82%
More

VIR and

Correlation & Price change

A.I.dvisor indicates that over the last year, VIR has been loosely correlated with BEAM. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if VIR jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VIR
1D Price
Change %
VIR100%
-17.82%
BEAM - VIR
55%
Loosely correlated
-4.99%
SLDB - VIR
53%
Loosely correlated
-2.29%
DNLI - VIR
52%
Loosely correlated
-0.79%
CADL - VIR
52%
Loosely correlated
-26.10%
EDIT - VIR
52%
Loosely correlated
+1.40%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
AAPB48.800.37
+0.75%
GraniteShares 2x Long AAPL Daily ETF (AAPB)
IJUL36.150.03
+0.08%
Innovator International Developed Power Buffer ETF - July (IJUL)
MHLA8.90N/A
N/A
Maiden Holdings Ltd
RDFI21.34-0.29
-1.33%
Rareview Dynamic Fixed Income ETF (RDFI)
CRF5.69-0.20
-3.40%
Cornerstone Total Return Fund